Medical

GlaxoSmithKline has announced results from the 26-week AUSTRI postmarketing study comparing the safety of Advair Diskus fluticasone propionate/salmeterol DPI to fluticasone propionate monotherapy for the treatment of asthma. According to GSK, the study demonstrated that… Read more . . .

GlaxoSmithKline has announced data from two studies demonstrating that the Incruse Ellipta umeclidinium DPI produced statistically significant increase in FEV1 at 12 weeks in COPD patients compared to tiotropium and was non-inferior to glycopyrronium. GSK… Read more . . .

Sunovion is presenting data from retrospective database analyses in two separate posters at the 2015 American College of Chest Physicians annual meeting that show similar rates of hospital readmission for COPD patients treated with Brovana… Read more . . .

The first patients have been dosed in a Phase 2a study of Verona Pharma’s RPL554 inhaled PDE3/PDE4 inhibitor as an addition to albuterol (salbutamol) and with ipratropium for the treatment of COPD, Verona said. The… Read more . . .

Serendex Pharmaceuticals has announced that data from a Phase 1 randomized, double blind, placebo controlled single ascending dose/multiple ascending dose trial showed that Molgradex inhaled GM-CSF (molgramostim) was well tolerated at all dose levels. No… Read more . . .

A Phase 2 study of Invion’s INV102 inhaled nadolol showed that smokers using the therapy were much more likely to stop smoking or significantly reduce the number of cigarettes they smoked than those using a… Read more . . .

Verona Pharma has announce that data from the third part of single ascending dose (SAD)/multiple ascending dose (MAD) trial of nebulized RPL554 in COPD patients show that the formulation was well tolerated at all doses… Read more . . .

Boehringer Ingelheim has announced new data from the ENERGITO and OTEMTO studies of the Stiolto tiotropium/olodaterol Respimat inhaler for the treatment of COPD. The FDA approved Stiolto Respimat in May 2015; in Europe, where the… Read more . . .

OptiNose has announced positive results from the NAVIGATE I Phase 3 trial of its OPN-375 intranasal fluticasone for the treatment of nasal polyposis demonstrating statistically significant reduction of symptoms and total polyp grade. In June… Read more . . .

Theravance Biopharma and Mylan announced that they have initiated Phase 3 studies for TD-4208 revefenacin inhalation solution for the treatment of COPD. The Phase 3 program includes 2 12-week efficacy studies plus a 12-month safety… Read more . . .